Alphabet's AI drug discovery unit Isomorphic Labs closed a $5 billion round co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new backer alongside Alphabet and all existing investors. It is the company's second billion-dollar raise in six months, following $2.1 billion in May 2026, and the capital will advance its in-house IsoDDE platform and push its drug pipeline toward clinical trials.
Isomorphic Labs
Alphabet-backed AI drug discovery company led by Demis Hassabis, focused on accelerating drug discovery with foundational simula
Curated Intelligence
Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, has closed a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining and all existing backers participating. Building on AlphaFold, its simulation-model engine has produced positive preclinical results in oncology and immunology and underpins deals with Eli Lilly, Novartis and Johnson & Johnson; the new capital is aimed at moving candidates into clinical trials.
Isomorphic Labs, Alphabet's AI-driven drug discovery unit led by Nobel laureate Demis Hassabis, has closed a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with a16z joining as a new investor and Alphabet continuing to commit heavily. The proceeds will fund foundational simulation models, expand internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.